Press Releases

Kristen M. Metza Joins Gilead as Vice President, Human Resources

FOSTER CITY, Calif.--(BUSINESS WIRE)--April 6, 2006--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Kristen M. Metza has joined the company as Vice President, Human Resources. Ms. Metza will report to President and Chief Executive Officer John C. Martin, PhD. She will serve as a member of Gilead's Executive Committee and will have responsibility for human resources across Gilead's U.S. and international operations.

"Kristen has a tremendous diversity and depth of experience in the field of human resources, and I am pleased to welcome her to the Gilead team," said Dr. Martin. "The success of our company is founded in the talent and expertise of our employees, and I look forward to working with Kristen to partner our human resources initiatives with our corporate strategy as Gilead continues to grow."

Ms. Metza has more than 20 years of experience in human resources programming, policy and management, holding positions of increasing responsibility and leadership. She joins Gilead from Abgenix, where she held the position of Senior Vice President, Human Resources. Ms. Metza was previously Vice President of Human Resources for Applied Biosystems and Quantum Corporation. She is a graduate of the University of Minnesota.

"Gilead has made remarkable progress delivering new therapies to patients with life-threatening diseases, and I am honored to have the opportunity to contribute to the company's mission," said Ms. Metza. "I look forward to working with my new colleagues to further the growth of Gilead in 2006 and beyond."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in the Gilead Annual Report on Form 10-K for the year ended December 31, 2005, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company's website at or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Erin Edgley, 650-522-5635 (Media)

SOURCE: Gilead Sciences, Inc.